OBJECTIVES: Comparative pharmacoeconomic assessment of COPD therapy of patients in GOLD 2-3 stages in Moscow health care system METHODS: Retrospective analysis of 130 cases during 1 year routine practice of patients with COPD in Moscow outpatients departments. Basic therapy strategies were obtaned: 1) monotherapy with indacaterol (14 pts. Low # of pts is because of the product was launched less than year ago); 2) monotherapy by tiotropium (33 pts), 3) fixed combination LABA + ICS (38 pts); 4) tiotropium plus fixed combination of LABA and ICS (45 pts). Cost of illness via calculation of direct medical costs on diagnostic, hospitalization, treatment of main disease and complications based on Federal Standards of COPD treatment and regional tariffs on cervices was estimated. Data on prices on medical products were obtained from State Register of medical products and www.aptechka.ru RESULTS: The most expencive strategy is management of group 4 - 86.5 KRUR/pt/year (1 Euro - 40 RUR) where 67% are costs on base drugs and 31% are hospitalization expenses. Usage of fixed combinations LABA + ICS is comparable with monotherapy by tiotropium, total costs are 47 and 49 KRUR/pt/year accordingly. But if the reason of main part of the costs in group 3 is hospitalization due to exacerbation - 69%, for group 2 - 61% are expenditures on tiotropium. The most preferable is treatment of group 1 - 32847 RUR/pt/year, where 55% - part on indacaterol, 42% - hospital treatment, 3% - urgent care. CONCLUSIONS: In spite of high price, indacaterol is the most economic preferable product for basic COPD treatment of patients in GOLD 2-3 stages